AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8358407 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized oral hygiene instruction and dental supplies (dental mirror and red disclosing tablets)
Number of subjects: 20
Study 8358407 — intervention group
Group type: COMPARATOR
Intervention: No oral hygiene instruction or supplies (Control)
Number of subjects: 20
Study 2439823 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg bopindolol
Number of subjects: 11
Study 2439823 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg bopindolol
Number of subjects: 11
Study 2439823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29396603 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular closure device (ACD) implantation
Number of subjects: 493
Study 29396603 — intervention group
Group type: COMPARATOR
Intervention: Limited lumbar discectomy alone (Control)
Number of subjects: 493
Study 26754303 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg paroxetine controlled-release tablet
Number of subjects: 12
Study 26754303 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg paroxetine controlled-release tablet
Number of subjects: 12
Study 26754303 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg paroxetine controlled-release tablet
Number of subjects: 12
Study 23953097 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD3 (Alcon Laboratories, Inc)
Number of subjects: 63
Study 23953097 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD1 (Alcon Laboratories, Inc)
Number of subjects: 63
Study 23953097 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS ZMA00 (Abbott Medical Optics)
Number of subjects: 63
Study 23953097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study 22897903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program in a rehabilitation centre, applied three times a week for 3 months
Number of subjects: 150
Study 22897903 — intervention group
Group type: COMPARATOR
Intervention: Flexibility and relaxation program in a rehabilitation centre, applied three times a week for 3 months
Number of subjects: 150
Study 22897903 — intervention group
Group type: COMPARATOR
Intervention: Daily physical activity program set at home using pedometers
Number of subjects: 150
Study 20214443 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 78
Study 20214443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG plus restoration (CTG + R)
Number of subjects: 78
Study 20214443 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG
Number of subjects: 78
Study 20214443 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF and CAF + R (overall data)
Number of subjects: 78
Study 18596310 — intervention group
Group type: COMPARATOR
Intervention: Standard glutamine-free amino acids (STD-PN)
Number of subjects: 59
Study 18596310 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine dipeptide-supplemented parenteral nutrition (GLN-PN)
Number of subjects: 59
Study 18596310 — intervention group
Group type: COMPARATOR
Intervention: STD-PN
Number of subjects: 59
Study 18596310 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN-PN
Number of subjects: 59
Study 16018759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 15
Study 12091203 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens
Number of subjects: 16
Study 12091203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10870905 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 0
Study 10870905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 0
Study 10870905 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood
Number of subjects: 0
Study 9096188 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 12 h for three doses then daily)
Number of subjects: 64
Study 9096188 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (1 g every 6 h i.v./p.o.)
Number of subjects: 64
Study 9096188 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 64
Study 9096188 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin
Number of subjects: 64
Study 8212206 — intervention group
Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 0
Study 8212206 — intervention group
Group type: COMPARATOR
Intervention: EC solution
Number of subjects: 0
Study 3090827 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (in 12 out of 17 patients)
Number of subjects: 35
Study 3090827 — intervention group
Group type: COMPARATOR
Intervention: Non-responsive ITP patients (not treated with splenectomy)
Number of subjects: 35
Study 3090827 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (in patients not cured)
Number of subjects: 35
Study 3090827 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy (in 2 patients after relapse)
Number of subjects: 35
Study 30260145 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cells therapy in addition to surgical left ventricular restoration (SVR)
Number of subjects: 30
Study 30260145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26584627 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study 26584627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 26584627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26091669 — intervention group
Group type: EXPERIMENTAL
Intervention: PREDICT intervention (allied dental personnel providing screening and preventive services in community settings with pay-for-performance compensation)
Number of subjects: 82000
Study 26091669 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (care delivered in dental offices without performance incentives)
Number of subjects: 82000
Study 23795877 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 332
Study 21701685 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 24
Study 21701685 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus protein (EX+PRO)
Number of subjects: 24
Study 21701685 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 19653787 — intervention group
Group type: EXPERIMENTAL
Intervention: smoked marijuana with 2.8% THC
Number of subjects: 20
Study 19653787 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 16722953 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard music (n = 22)
Number of subjects: 60
Study 16722953 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterning music (n = 18)
Number of subjects: 60
Study 16722953 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 60
Study 15204043 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong
Number of subjects: 36
Study 15204043 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 36
Study 10742708 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 201
Study 10742708 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 201
Study 10742708 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 201
Study 9041468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon-beta (IFN-beta) at a dosage of 6 million units three times per week for 6 months
Number of subjects: 90
Study 9041468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon-beta (IFN-beta)
Number of subjects: 90
Study 9041468 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 90
Study 7701045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 10 mg
Number of subjects: 10
Study 7701045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsapirone 20 mg
Number of subjects: 10
Study 7701045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3299181 — intervention group
Group type: EXPERIMENTAL
Intervention: Five different techniques of cuff closure during transvaginal hysterectomy
Number of subjects: 112
Study 29788545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with Rosa damascena at a 4% concentration
Number of subjects: 66
Study 29788545 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving aromatherapy with 100% sweet almond oil
Number of subjects: 66
Study 28219804 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral posterior‐to‐anterior mobilization (PA) applied to the neck
Number of subjects: 44
Study 28219804 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PA-P) applied to the neck (light touch on the right 6th cervical vertebra)
Number of subjects: 44
Study 28219804 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PA and PA-P
Number of subjects: 44
Study 28219804 — intervention group
Group type: EXPERIMENTAL
Intervention: PA
Number of subjects: 44
Study 26174461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, increased to 100 mg after 1 week)
Number of subjects: 12
Study 26174461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23446104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 15 weeks
Number of subjects: 48
Study 21203367 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 59
Study 21203367 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 59
Study 18286296 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB), 1.25 mg, 5‐7 days before PPV
Number of subjects: 22
Study 18286296 — intervention group
Group type: COMPARATOR
Intervention: Direct PPV (Control group)
Number of subjects: 22
Study 16448519 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500/2.5 mg tablets (initial daily dose 1000/5 mg)
Number of subjects: 318
Study 16448519 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg plus rosiglitazone 4 mg (initial daily dose 1000-2000 mg + 4 mg)
Number of subjects: 318
Study 16448519 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide
Number of subjects: 318
Study 16448519 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus rosiglitazone
Number of subjects: 318
Study 12923399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure
Number of subjects: 3007
Study 12923399 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP)
Number of subjects: 3007
Study 12923399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP)
Number of subjects: 3007
Study 12923399 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 3007
Study 10708289 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 167
Study 10708289 — intervention group
Group type: COMPARATOR
Intervention: RTV/SQV/d4T
Number of subjects: 167
Study 9401428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pleasant odor
Number of subjects: 80
Study 9401428 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpleasant odor
Number of subjects: 80
Study 9401428 — intervention group
Group type: COMPARATOR
Intervention: No-odor control
Number of subjects: 80
Study 8587251 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 180
Study 8587251 — intervention group
Group type: EXPERIMENTAL
Intervention: non-DD genotype
Number of subjects: 180
Study 2667746 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant progestagen therapy (progesterone)
Number of subjects: 1148
Study 2667746 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional therapy)
Number of subjects: 1148
Study 1069314 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mcg/kg N,N-Dimethyltryptamine (DMT) i.m.
Number of subjects: 38
Study 1069314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31121324 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) until progression, unacceptable toxicity, or consent withdrawal
Number of subjects: 1426
Study 29028930 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX (smartphone application)
Number of subjects: 46
Study 29028930 — intervention group
Group type: COMPARATOR
Intervention: Control (without MAX)
Number of subjects: 46
Study 26041274 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate injection of botulinum toxin type A (group A)
Number of subjects: 34
Study 26041274 — intervention group
Group type: COMPARATOR
Intervention: 1-month delayed injection of botulinum toxin type A (group B)
Number of subjects: 34
Study 26041274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 34
Study 25099322 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol-remifentanil
Number of subjects: 30
Study 25099322 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthesia with desflurane-remifentanil
Number of subjects: 30
Study 22230384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10:0.4 mg, low FA group)
Number of subjects: 480
Study 22230384 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril-FA tablet (10:0.8 mg, high FA group)
Number of subjects: 480
Study 22230384 — intervention group
Group type: COMPARATOR
Intervention: Enalapril only (10 mg, control group)
Number of subjects: 480
Study 18996525 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.75 g/day
Number of subjects: 65
Study 18996525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 17204992 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Temporal Bone (VR TB) simulator
Number of subjects: 19
Study 16192600 — intervention group
Group type: EXPERIMENTAL
Intervention: YES-ASP (20 weekly doses of high-dose L-asparaginase at 25,000 IU/m2)
Number of subjects: 494
Study 16192600 — intervention group
Group type: COMPARATOR
Intervention: NO-ASP (no high-dose L-asparaginase)
Number of subjects: 494
Study 16192600 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 494
Study 12475845 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 232
Study 12475845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 9806581 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-positive for C. trachomatis DNA
Number of subjects: 10
Study 9806581 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chlamydial RNA molecules
Number of subjects: 10
Study 8961906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) at a dosage of 2,000 mg/day
Number of subjects: 221
Study 8961906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 1820496 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 20
Study 1820496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7295884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (30 mg) in combination with standard-release pindolol (7.5 mg)
Number of subjects: 0
Study 7295884 — intervention group
Group type: COMPARATOR
Intervention: Standard-release isosorbide dinitrate alone (30 mg)
Number of subjects: 0
Study 7295884 — intervention group
Group type: COMPARATOR
Intervention: Standard-release pindolol alone (7.5 mg)
Number of subjects: 0
Study 7295884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release pindolol (7.5 mg) in combination with isosorbide dinitrate
Number of subjects: 0
Study 31503365 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Delivery (ED) at 34 weeks
Number of subjects: 21
Study 31503365 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 21
Study 31843012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 55
Study 31843012 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 55
Study 31843012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 28116754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esoxx (hyaluronic acid-chondroitin sulphate based bioadhesive formulation) plus standard dose PPIs
Number of subjects: 154
Study 28116754 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard dose PPIs
Number of subjects: 154
Study 28116754 — intervention group
Group type: EXPERIMENTAL
Intervention: Esoxx plus standard dose PPIs
Number of subjects: 154
Study 25944731 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates
Number of subjects: 2464
Study 23352732 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy (TT)
Number of subjects: 193
Study 23352732 — intervention group
Group type: COMPARATOR
Intervention: Bipolar scissors tonsillectomy (TE)
Number of subjects: 193
Study 21811062 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried California Mission figs (120 g/day) added to usual diet for 5 weeks
Number of subjects: 83
Study 21811062 — intervention group
Group type: COMPARATOR
Intervention: Usual diet for 5 weeks
Number of subjects: 83
Study 19455481 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery beverage (40 g CHO + 20 g PRO)
Number of subjects: 8
Study 19455481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 16938699 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger associative fan (more associates paired with event-based cues)
Number of subjects: 0
Study 16938699 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute strength of an association
Number of subjects: 0
Study 16938699 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity of background words
Number of subjects: 0
Study 15549278 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment (paroxetine or citalopram) for 4 weeks
Number of subjects: 19
Study 15549278 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-clinical sample)
Number of subjects: 19
Study 11104597 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified menu
Number of subjects: 0
Study 11104597 — intervention group
Group type: COMPARATOR
Intervention: Normal menu
Number of subjects: 0
Study 1626500 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg twice daily)
Number of subjects: 58
Study 1626500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 6497566 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (fixed doses)
Number of subjects: 0
Study 31403675 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 8184
Study 31403675 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 8184
Study 29229955 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk (3.5% fat)
Number of subjects: 18
Study 29229955 — intervention group
Group type: COMPARATOR
Intervention: Skimmed milk (0.1% fat)
Number of subjects: 18
Study 27072159 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral position for 15 minutes followed by right lateral position for another 15 minutes (Group 1)
Number of subjects: 69
Study 27072159 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position for 15 minutes followed by left lateral position for another 15 minutes (Group 2)
Number of subjects: 69
Study 24074763 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant 5-flurouracil, alpha-interferon and interleukin-2
Number of subjects: 309
Study 24074763 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 309
Study 23082382 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide
Number of subjects: 60
Study 23082382 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching with 16% carbamide peroxide
Number of subjects: 60
Study 20442660 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 7.8 microg kg(‐1) (IED95)
Number of subjects: 68
Study 20442660 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg(‐1)
Number of subjects: 68
Study 20442660 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil doses (3, 4, 5, or 6 microg kg(‐1))
Number of subjects: 68
Study 19100036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 232
Study 19100036 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical operations
Number of subjects: 232
Study 19100036 — intervention group
Group type: COMPARATOR
Intervention: Congenital Heart Disease (CHD)
Number of subjects: 232
Study 15472910 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Etoposide
Number of subjects: 495
Study 15472910 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 495
Study 15472910 — intervention group
Group type: COMPARATOR
Intervention: 3-drug combination (actinomycin-D, vincristine, bleomycin)
Number of subjects: 495
Study 15472910 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 495
Study 12583787 — intervention group
Group type: COMPARATOR
Intervention: NEI-VFQ scores for participants with advanced age-related macular degeneration, severe nuclear opacity, reduced visual acuity, or cataract surgery
Number of subjects: 4077
Study 12583787 — intervention group
Group type: EXPERIMENTAL
Intervention: NEI-VFQ subscales
Number of subjects: 4077
Study 10565801 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day)
Number of subjects: 15
Study 8902369 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated detection method using textural features in scintigraphic images
Number of subjects: 23
Study 2007841 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg b.i.d. for 2 weeks followed by 10 mg b.i.d. for a further 2 weeks)
Number of subjects: 18
Study 2007841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6442151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg or 500 mg, 12-hourly for 10 days
Number of subjects: 40
Study 31656505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (group A, n=25)
Number of subjects: 40